- Home
- FWRG vs CRGX Comparison
FWRG vs CRGX Comparison
Compare FWRG & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- CRGX
- Stock Information
- Founded
- FWRG 1983
- CRGX 2021
- Country
- FWRG United States
- CRGX United States
- Employees
- FWRG N/A
- CRGX N/A
- Industry
- FWRG Restaurants
- CRGX
- Sector
- FWRG Consumer Discretionary
- CRGX
- Exchange
- FWRG Nasdaq
- CRGX Nasdaq
- Market Cap
- FWRG 1.0B
- CRGX 964.5M
- IPO Year
- FWRG 2021
- CRGX 2023
- Fundamental
- Price
- FWRG $18.24
- CRGX $16.23
- Analyst Decision
- FWRG Strong Buy
- CRGX Strong Buy
- Analyst Count
- FWRG 10
- CRGX 7
- Target Price
- FWRG $23.50
- CRGX $30.33
- AVG Volume (30 Days)
- FWRG 1.1M
- CRGX 198.9K
- Earning Date
- FWRG 11-07-2024
- CRGX 11-12-2024
- Dividend Yield
- FWRG N/A
- CRGX N/A
- EPS Growth
- FWRG N/A
- CRGX N/A
- EPS
- FWRG 0.33
- CRGX N/A
- Revenue
- FWRG $997,252,000.00
- CRGX N/A
- Revenue This Year
- FWRG $16.43
- CRGX N/A
- Revenue Next Year
- FWRG $15.22
- CRGX N/A
- P/E Ratio
- FWRG $55.08
- CRGX N/A
- Revenue Growth
- FWRG 19.77
- CRGX N/A
- 52 Week Low
- FWRG $12.90
- CRGX $13.56
- 52 Week High
- FWRG $25.98
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- FWRG 53.66
- CRGX 35.57
- Support Level
- FWRG $16.82
- CRGX $15.27
- Resistance Level
- FWRG $21.50
- CRGX $16.68
- Average True Range (ATR)
- FWRG 1.00
- CRGX 1.59
- MACD
- FWRG -0.26
- CRGX -0.54
- Stochastic Oscillator
- FWRG 27.36
- CRGX 12.42
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.